{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "Azedra",
      "indication": "1 INDICATIONS AND USAGE AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. AZEDRA is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. ( 1 )",
      "manufacturer": "Progenics Pharmaceuticals, Inc.",
      "splSetId": "3423ac0f-9585-4abf-a8ba-a5123a8277ee"
    }
  ],
  "id": "Iobenguane_I-131",
  "nciThesaurus": {
    "casRegistry": "77679-27-7",
    "chebiId": "",
    "chemicalFormula": "C8H10IN3",
    "definition": "An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.",
    "fdaUniiCode": "Q461L7AK4R",
    "identifier": "C970",
    "preferredName": "Iobenguane I-131",
    "semanticType": "Indicator, Reagent, or Diagnostic Aid",
    "subclassOf": [
      "C2124"
    ],
    "synonyms": [
      "(131)I-MIBG",
      "131I-MIBG",
      "I 131 Meta-iodobenzylguanidine",
      "I-131 Metaiodobenzylguanidine",
      "IOBENGUANE I-131",
      "Iobenguane (131I)",
      "Iobenguane I 131",
      "Iobenguane I-131",
      "Iodine I 131 Metaiodobenzylguanidine",
      "MIBG I-131",
      "iodine I 131 metaiodobenzylguanidine"
    ]
  }
}